NYSE:BMYPharmaceuticals
Is Positive Camzyos Adolescent Trial Data Altering The Investment Case For Bristol-Myers Squibb (BMY)?
In late March 2026, Bristol Myers Squibb reported that its Phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy met its primary endpoint, delivering a clinically meaningful and statistically significant reduction in Valsalva LVOT gradient and supportive safety data versus placebo over 28 weeks.
The findings, showcased at the American College of Cardiology 2026 meeting and published in The New England Journal of Medicine, highlight...